GrantPostedDiscretionary

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

National Institutes of Health
PAR-25-064
Application Deadline
Sep 7, 2026
105 days left
Days Remaining
105
Until deadline
Award Ceiling
Total Program Funding

Grant Opportunity Analysis

The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

Eligible Applicants

Others
Additional Eligibility Information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Grant Documents

2 Files
PAR-25-064-Full-Announcement.html
HTML0 KBNov 19, 2024
AI Summary
No AI summary available for this file.
PAR-25-064.html
HTML129 KBNov 19, 2024
AI Summary
The Department of Health and Human Services, through the National Institutes of Health, invites applications for an R21 exploratory research grant focusing on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance understanding of the neurobiological and behavioral mechanisms underlying NPS, such as aggression, anxiety, and agitation, which can significantly impact care and worsen patient outcomes. Investigators pursuing high-risk projects without preliminary data may apply for the R21 mechanism, while those with established data are encouraged to consider R01 grants. Key dates include application openings on January 16, 2025, with funding capped at $275,000 over two years. The document emphasizes multi-level analysis and innovative methodologies to identify treatment targets and improve intervention strategies for NPS. Applications must align with rigorous application instructions and adhere to compliance regulations, with successful submissions undergoing a peer review process followed by funding decisions based on scientific merit and relevance to program priorities. This initiative is part of a broader national effort to address the complexities and challenges associated with Alzheimer's disease and dementia care.

Related Grant Opportunities

Project Timeline

postedOriginal Opportunity PostedNov 18, 2024
deadlineApplication DeadlineSep 7, 2026
expiryArchive DateOct 13, 2026

Funding Details

No cost sharing required

Agency & Classification

Agency
National Institutes of Health(HHS-NIH11)
Funding Category
Health
Funding Instrument
Grant

Grantor Contact

CFDA Numbers

93.866

Official Sources